Spots Global Cancer Trial Database for cholangiocarcinoma
Every month we try and update this database with for cholangiocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Liver Cancer Registry Platform | NCT04510740 | Hepatocellular ... Cholangiocarcin... | Physician's cho... | 18 Years - | iOMEDICO AG | |
| Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) | NCT02082522 | Hilar Cholangio... | Photodynamic th... Stenting proced... Chemotherapy re... | 18 Years - | Concordia Laboratories Inc. | |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | NCT04068194 | Cholangiocarcin... Gallbladder Car... Stage III Gallb... Stage III Hilar... Stage III Intra... Stage IV Gallbl... Stage IV Hilar ... Stage IV Intrah... | Avelumab Biopsy Biospecimen Col... Computed Tomogr... Hypofractionate... Peposertib | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | NCT03943043 | Cholangiocarcin... | nab-paclitaxel | 18 Years - | Istituto Clinico Humanitas | |
| International Registry on Cholangiocarcinoma Treatment | NCT01920503 | Cholangiocarcin... | Doxorubicin | 18 Years - 75 Years | International Group of Endovascular Oncology | |
| Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a LCD Stent | NCT01875549 | Obstruction of ... Cholangiocarcin... Hepatocellular ... Malignant Lymph... Gall Bladder Ca... | stent insertion Endoscopic retr... | 18 Years - | Samsung Medical Center | |
| A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | NCT05967182 | Cholangiocarcin... | Pembrolizumab Gemcitabine Cisplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study | NCT04243057 | Cholangiocarcin... | 18 Years - | Beijing Tsinghua Chang Gung Hospital | ||
| Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | NCT02174575 | Hepatocellular ... Hepatoma Cholangiocarcin... Gallbladder Neo... | Sevoflurane Desflurane | 20 Years - | Tokyo Medical and Dental University | |
| PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. | NCT05207735 | Cholangiocarcin... | Sintilimab | 18 Years - 75 Years | Henan Cancer Hospital | |
| Study of Pembrolizumab and Olaparib in Bile Duct Cancer | NCT04306367 | Cholangiocarcin... | Pembrolizumab Olaparib | 18 Years - | Georgetown University | |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | NCT02568267 | Breast Cancer Cholangiocarcin... Colorectal Canc... Head and Neck N... Lymphoma, Large... Melanoma Neuroendocrine ... Non-Small Cell ... Ovarian Cancer Pancreatic Canc... Papillary Thyro... Primary Brain T... Renal Cell Carc... Sarcomas Salivary Gland ... Adult Solid Tum... | Entrectinib | 18 Years - | Hoffmann-La Roche | |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | NCT06010862 | Gastric Cancer Colon Cancer Pancreas Cancer Esophagus Cance... Cholangiocarcin... Lung Cancer Breast Cancer | CEA CAR-T cells CEA CAR-T cells | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | NCT04233567 | Advanced Malign... Cholangiocarcin... Metastatic Mali... Refractory Mali... | Infigratinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | NCT03829436 | Hepatocellular ... Metastatic Cast... Renal Cell Carc... Non-small Cell ... Colorectal Canc... Squamous Cell C... Triple-Negative... Urothelial Carc... Cholangiocarcin... GastroEsophagea... Pancreatic Canc... Sarcoma | Part 1 TPST-112... Part 2 TPST-112... Part 3 TPST-112... Part 4 TPST-112... | 18 Years - | Tempest Therapeutics | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma | NCT02730611 | Morbid Obesity Vertical Sleeve... Metabolic Syndr... Hepatocellular ... Cholangiocarcin... Disorder of Bil... | 18 Years - | Assistance Publique - Hôpitaux de Paris | ||
| Registry for Advanced Endoscopy | NCT05187312 | Cholangiocarcin... Pancreatic Canc... Sclerosing Chol... | Endoscopic retr... Endoscopic ultr... | 18 Years - | Region Stockholm | |
| Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | NCT02073994 | Cholangiocarcin... Chondrosarcoma Glioma Other Advanced ... | AG-120 | 18 Years - | Servier | |
| RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma | NCT05028439 | Cholangiocarcin... | radiofrequency ... Chemotherapy dr... | 18 Years - 75 Years | First People's Hospital of Hangzhou | |
| Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer | NCT01915225 | Colorectal Neop... Gastric Neoplas... Cholangiocarcin... Bile Duct Cance... Pancreas Cancer | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | NCT03250273 | Metastatic Chol... Cholangiocarcin... Pancreatic Canc... Metastatic Panc... Unresectable Pa... Unresectable Ch... | Entinostat Nivolumab Entinostat Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy | NCT02452970 | Cholangiocarcin... | RRx-001 Gemcitabine and... | 18 Years - | EpicentRx, Inc. | |
| A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection | NCT01043172 | Cholangiocarcin... | Gemcitabine | 18 Years - | National Cancer Center, Korea | |
| Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy | NCT06048289 | Biliary Tract T... Cholangiocarcin... | Blood samples, ... | 18 Years - | Zhejiang Cancer Hospital | |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | NCT05848739 | Breast Cancer M... Pancreatic Canc... NSCLC, Metastat... Synovial Sarcom... Colon Cancer Metastatic Colo... Melanoma Recurr... Metastatic Skin... Melanoma Stage ... Triple Negative... TNBC - Triple-N... Cholangiocarcin... Ovarian Cancer Metastatic Mela... Hepatocellular ... | ST316 | 18 Years - | Sapience Therapeutics | |
| T-EUS for Gastrointestinal Disorders: A Multicenter Registry | NCT01522573 | Cholangiocarcin... Pancreatic Canc... Bile Duct Cance... Biliary Strictu... Biliary Obstruc... Stent Obstructi... Proximal Duct S... Distal Duct Str... Ampullary Cance... Biliary Sphinct... Impacted Stones Chronic Pancrea... Peri-ampullary ... Altered Anatomy | EUS guided ERCP | 18 Years - | Weill Medical College of Cornell University | |
| Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter | NCT00160836 | Pancreatic Neop... Cholangiocarcin... Pancreatitis | Tissue sampling... | 18 Years - | University Hospital, Geneva | |
| Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures | NCT00653978 | Cholangiocarcin... | ERCP plus one b... ERCP plus two b... | 18 Years - 90 Years | Changhai Hospital | |
| ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy | NCT02609958 | Cholangiocarcin... | Varlitinib | - | ASLAN Pharmaceuticals | |
| Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) | NCT00955149 | Primary Scleros... Trisomy 7 Cholangiocarcin... Chemoprevention | Erlotinib (Tarc... | 18 Years - | Mayo Clinic | |
| Study of EOC317 in Chinese Patients With Advanced Solid Tumors | NCT03583125 | Solid Tumor | EOC317 | 18 Years - | Taizhou EOC Pharma Co., Ltd. | |
| The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer | NCT03637569 | Pancreas Cancer Cholangiocarcin... Gallbladder Can... | Measurement of ... | 18 Years - | Samsung Medical Center | |
| Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | NCT04782804 | Cholangiocarcin... | Capecitabine PD-1 Antibody（T... | 18 Years - 75 Years | Fudan University | |
| Avastin and Tarceva for Upper Gastrointestinal Cancers | NCT00350753 | Cholangiocarcin... Gallbladder Can... | Erlotinib and b... | 18 Months - | Rigshospitalet, Denmark | |
| Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) | NCT04989218 | Cholangiocarcin... | Novel combinati... | 18 Years - 89 Years | University of Alabama at Birmingham | |
| Neoadjuvant Therapy in Biliary Adenocarcinoma | NCT04480190 | Cholangiocarcin... Biliary Cancer | Gemcitabine Cisplatin Fluorouracil Short course Ch... | 18 Years - | University of Cincinnati | |
| Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers | NCT04459273 | Bladder Carcino... Cervical Carcin... Cholangiocarcin... Hematopoietic a... Hepatocellular ... Malignant Adren... Malignant Brain... Malignant Pleur... Malignant Skin ... Malignant Solid... Malignant Testi... Malignant Thymu... Neuroendocrine ... Thyroid Gland C... Urothelial Carc... Cancer of Unkno... | Computed Tomogr... Gallium Ga 68 F... Positron Emissi... 18F-FDG | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors | NCT02665494 | Cholangiocarcin... | 18 Years - | Fondazione del Piemonte per l'Oncologia | ||
| Bilioenteric Anastomosis by Magnetic Compressive Technique | NCT03774589 | Pancreatic Canc... Cholangiocarcin... Bile Duct Injur... Choledochal Cys... Biliary Calculi | Magnetic Compre... Manual Anastomo... | 18 Years - 75 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | NCT03924466 | Metastatic Brea... Locally Advance... Cancer of Pancr... Solid Tumor Wit... Salivary Gland ... Gastric Cancer Endometrial Can... Uterine Cancer Non Small Cell ... Biliary Tract C... Cholangiocarcin... Colorectal Canc... Urothelial Carc... Prostate Cancer | 68GaNOTA-Anti-H... | 18 Years - | Universitair Ziekenhuis Brussel | |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | NCT05432193 | Pancreatic Duct... Colorectal Canc... Esophageal Canc... Melanoma (Skin) Soft Tissue Sar... Head and Neck S... Cholangiocarcin... | [Ga-68]-PNT6555 [Lu-177]-PNT655... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC | NCT01267344 | Cholangiocarcin... Adenocarcinoma ... | gemcitabine, ox... cetuximab, gemc... | 20 Years - | National Health Research Institutes, Taiwan | |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | NCT05451849 | Mesothelioma Mesotheliomas P... Mesothelioma, M... Mesothelioma Pe... Ovarian Cancer Ovarian Serous ... Pancreatic Canc... Pancreatic Aden... Colorectal Canc... Triple Negative... TNBC - Triple-N... Ovarian Adenoca... Pancreatic Neop... Colorectal Neop... Ovarian Neoplas... Cholangiocarcin... Non Small Cell ... | TC-510 Fludarabine Cyclophosphamid... | 18 Years - | TCR2 Therapeutics | |
| Prospective Evaluation of Biliary Tissue Sampling With ERCP | NCT04572711 | Cholangiopancre... Biliary Strictu... Biliary Tract D... Cholangiocarcin... | 18 Years - | Mayo Clinic | ||
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | NCT04521686 | Cholangiocarcin... Chondrosarcoma Glioma Any Solid Tumor | LY3410738 Gemcitabine Cisplatin Durvalumab | 18 Years - | Eli Lilly and Company | |
| Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours | NCT00475956 | Neoplasms | AZD2171 AZD0530 | 18 Years - | AstraZeneca | |
| Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic . | NCT03140007 | Cholangiocarcin... Biliary Strictu... | single operator... ERCP guided bru... | 18 Years - 75 Years | Asian Institute of Gastroenterology, India | |
| Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer | NCT04642664 | Biliary Tract C... Cholangiocarcin... Biomarker Hepatobiliary N... | Apatinib plus C... | 18 Years - | Peking Union Medical College Hospital | |
| Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | NCT04507503 | Advanced Cholan... | TAS-120 | 18 Years - | Taiho Oncology, Inc. | |
| Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | NCT03924466 | Metastatic Brea... Locally Advance... Cancer of Pancr... Solid Tumor Wit... Salivary Gland ... Gastric Cancer Endometrial Can... Uterine Cancer Non Small Cell ... Biliary Tract C... Cholangiocarcin... Colorectal Canc... Urothelial Carc... Prostate Cancer | 68GaNOTA-Anti-H... | 18 Years - | Universitair Ziekenhuis Brussel | |
| High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery | NCT02757859 | Acinar Cell Car... Ampulla of Vate... Cholangiocarcin... Duodenal Adenoc... Pancreatic Aden... Pancreatic Duct... Pancreatic Intr... Periampullary A... | Pancreatectomy Lavage Pancreatectomy Lavage Pancreatectomy | 18 Years - | Thomas Jefferson University | |
| Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy | NCT01642875 | Pancreatic Canc... Cancer of the D... Cholangiocarcin... Chronic Pancrea... | Enteral nutriti... Oral nutrition | 18 Years - | Medical University of Warsaw | |
| Precise Treatment System of Biliary Malignancies Based on Special Disease Database | NCT03499782 | Cholangiocarcin... Gall Bladder Ca... Biliary System ... | 18 Years - 80 Years | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | ||
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | NCT03602079 | HER2-positive B... HER2 Gene Mutat... HER-2 Gene Ampl... HER2 Positive G... Salivary Gland ... Salivary Gland ... Salivary Gland ... Salivary Gland ... Lung Cancer Colo-rectal Can... Rare Diseases Solid Tumor Recurrent Gastr... Recurrent Colon... Recurrent Breas... Head and Neck C... Head and Neck C... Bladder Cancer Cervical Cancer Liver Cancer Bile Duct Cance... Urologic Cancer Pancreatic Canc... Prostate Cancer Recurrent Prost... Rectal Cancer Recurrent Ovari... Recurrent Renal... Rectal Cancer S... Rectal Cancer S... Rectal Cancer S... Skin Cancer Mouth Cancer Lip Cancer Stag... Tongue Cancer Breast Neoplasm... Larynx Cancer Tonsil Cancer Palate Cancer Mucoepidermoid ... Primary Periton... Mucinous Adenoc... Mucinous Breast... Cholangiocarcin... | A166 | 18 Years - | Klus Pharma Inc. | |
| Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand | NCT05321992 | Cholangiocarcin... Liver Fluke-Rel... Opisthorchiasis | eCHEC program | 20 Years - | McMaster University | |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | NCT04430842 | Astrocytoma Brain Cancer Brain Metastase... Bladder Cancer Breast Cancer Cervical Cancer Cholangiocarcin... Colorectal Canc... Esophagus Cance... Gastric Cancer Head and Neck C... Kidney Cancer Liver Cancer Lung Cancer Melanoma Ovarian Cancer Pancreatic Canc... Pleural Mesothe... Prostate Cancer Sarcoma Tongue Cancer Thymic Carcinom... Urinary Tract C... | QBS10072S | 18 Years - | Quadriga Biosciences, Inc. | |
| Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | NCT05292859 | Gynecologic Can... Colorectal Canc... Pancreatic Canc... Non-small Cell ... Cholangiocarcin... Ovarian Cancer Ovary Neoplasm Squamous Cell L... Adenocarcinoma ... Adenosquamous C... | Neoantigen spec... | 18 Years - | Alaunos Therapeutics | |
| Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) | NCT04203160 | Biliary Tract C... | CPI 613 Gemcitabine Cisplatin | 18 Years - | University of Michigan Rogel Cancer Center | |
| Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma | NCT02108145 | Hilar Cholangio... | bilateral metal... unilateral meta... | 18 Years - 90 Years | Air Force Military Medical University, China | |
| A Study of SGN-B7H4V in Advanced Solid Tumors | NCT05194072 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... Triple Negative... HER2 Negative B... Hormone Recepto... Endometrial Neo... Carcinoma, Non-... Cholangiocarcin... Gallbladder Car... Adenoid Cystic ... | SGN-B7H4V | 18 Years - | Seagen Inc. | |
| Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | NCT05411133 | Gastrointestina... Cholangiocarcin... Liver Cancer Colorectal Aden... Pancreatic Canc... Gastric Cancer Esophageal Aden... Gastroesophagea... | Cabotamig (ARB2... | 18 Years - | Arbele Limited | |
| High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery | NCT02757859 | Acinar Cell Car... Ampulla of Vate... Cholangiocarcin... Duodenal Adenoc... Pancreatic Aden... Pancreatic Duct... Pancreatic Intr... Periampullary A... | Pancreatectomy Lavage Pancreatectomy Lavage Pancreatectomy | 18 Years - | Thomas Jefferson University | |
| Milademetan in Advanced/Metastatic Solid Tumors | NCT05012397 | Solid Tumors Head and Neck C... Cholangiocarcin... Sarcoma Lung Adenocarci... Bladder Urothel... Stomach Adenoca... Breast Cancer I... Ovarian Carcino... Cervical Cancer Non Small Cell ... Gastric Cancer Biliary Tract C... Melanoma Pancreas Cancer MDM2 Gene Ampli... Testicular Germ... Adrenocortical ... | RAIN-32 | 18 Years - | Rain Oncology Inc | |
| Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection? | NCT00733200 | Cholangiocarcin... Surgical Treatm... Hepatectomy | Minor or Major ... | 26 Years - 72 Years | Huazhong University of Science and Technology | |
| RFA for Malignant Biliary Obstruction | NCT03166436 | Cholangiocarcin... Pancreas Cancer | Radiofrequency ... Biliary stentin... | 18 Years - | Institute for Clinical and Experimental Medicine | |
| Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD | NCT01673269 | Choledocholithi... Cholangiocarcin... Benign Strictur... | Blood culture (... | 18 Years - 80 Years | Texas Tech University Health Sciences Center, El Paso | |
| The PLATON Network | NCT05489250 | Hepatocellular ... Cholangiocarcin... Gallbladder Can... Pancreatic Canc... Oesophageal Can... Stomach Cancer | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | ||
| Radiofrequency Ablation for Biliopancreatic Malignancy | NCT02468076 | Pancreas Cancer Cholangiocarcin... Obstructive Jau... | Radiofrequency ... | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | NCT03656536 | Unresectable Ch... Metastatic Chol... | Pemigatinib Gemcitabine Cisplatin | 18 Years - | Incyte Corporation | |
| Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | NCT04782804 | Cholangiocarcin... | Capecitabine PD-1 Antibody（T... | 18 Years - 75 Years | Fudan University | |
| Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer | NCT00660140 | Cholangiocarcin... Gallbladder Can... | Gemcitabine Carboplatin | 18 Years - | Washington University School of Medicine | |
| Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders | NCT01438385 | Ampullary Cance... Duodenal Cancer Bile Duct Cance... Bile Duct Disor... Gallstones Obstructive Jau... Pancreatic Diso... Colorectal Canc... Esophageal Canc... Barrett's Esoph... Gastric Maligna... Pancreatic Canc... Pediatric Gastr... Cholangiocarcin... Pancreatic Pseu... Acute and Chron... Recurrent Pancr... Cholangitis Bile Leak Biliary Strictu... Pancreatic Divi... Biliary and Pan... Choledocholithi... | Interventional ... | 18 Years - | Weill Medical College of Cornell University | |
| Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | NCT04233567 | Advanced Malign... Cholangiocarcin... Metastatic Mali... Refractory Mali... | Infigratinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement | NCT04256980 | Cholangiocarcin... | Pemigatinib | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) | NCT02082522 | Hilar Cholangio... | Photodynamic th... Stenting proced... Chemotherapy re... | 18 Years - | Concordia Laboratories Inc. | |
| Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | NCT02128282 | Cholangiocarcin... | CX-4945 Cisplatin Gemcitabine | 18 Years - | Senhwa Biosciences, Inc. | |
| Personal Resilience Empowerment Program Study | NCT03644173 | Lung Cancer Cholangiocarcin... Pancreatic Canc... Liver Cancer | Personal Resili... | 18 Years - | Hackensack Meridian Health | |
| Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma | NCT01755013 | Cholangiocarcin... Biliary Strictu... Biliary Obstruc... Bile Duct Cance... | Photodynamic Th... | 18 Years - | Weill Medical College of Cornell University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
